See more : Minnova Corp. (MCI.V) Income Statement Analysis – Financial Results
Complete financial analysis of Alpine Immune Sciences, Inc. (ALPN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Alpine Immune Sciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- BRIM Biotechnology, Inc. (6885.TWO) Income Statement Analysis – Financial Results
- China Tungsten And Hightech Materals Co.,Ltd (000657.SZ) Income Statement Analysis – Financial Results
- GFJ ESG Acquisition I SE (GFJ1.F) Income Statement Analysis – Financial Results
- Santander Bank Polska S.A. (BKZHF) Income Statement Analysis – Financial Results
- Nidec Corporation (NJDCY) Income Statement Analysis – Financial Results
Alpine Immune Sciences, Inc. (ALPN)
About Alpine Immune Sciences, Inc.
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 58.88M | 30.06M | 23.44M | 9.34M | 1.74M | 705.00K | 1.73M | 2.95M | 492.00K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 80.90M | 597.00K | 620.00K | 27.19M | 35.85M | 28.97M | 10.63M | 143.00K | 66.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -22.03M | 29.47M | 22.82M | -17.85M | -34.11M | -28.27M | -8.90M | 2.81M | 426.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | -37.41% | 98.01% | 97.36% | -191.22% | -1,960.17% | -4,009.22% | -513.86% | 95.15% | 86.59% | 0.00% | 0.00% | 0.00% |
| Research & Development | 80.90M | 70.24M | 58.74M | 27.19M | 35.85M | 28.97M | 10.63M | 23.32M | 16.05M | 12.20M | 13.14M | 7.10M |
| General & Administrative | 22.22M | 17.97M | 14.56M | 10.90M | 9.47M | 8.36M | 6.08M | 8.59M | 6.84M | 2.29M | 2.14M | 1.93M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 22.22M | 17.97M | 14.56M | 10.90M | 9.47M | 8.36M | 6.08M | 8.59M | 6.84M | 2.29M | 2.14M | 1.93M |
| Other Expenses | 0.00 | -97.00K | -4.00K | 1.33M | 812.00K | 1.20M | 0.00 | 0.00 | 80.00K | 296.34K | 0.00 | 150.94K |
| Operating Expenses | 103.13M | 88.21M | 73.30M | 38.08M | 45.31M | 37.33M | 16.71M | 31.90M | 22.90M | 14.49M | 15.28M | 9.03M |
| Cost & Expenses | 103.13M | 88.21M | 73.30M | 38.08M | 45.31M | 37.33M | 16.71M | 31.90M | 22.90M | 14.49M | 15.28M | 9.03M |
| Interest Income | 11.85M | 3.29M | 259.00K | 245.00K | 1.25M | 1.30M | 542.00K | 439.00K | 80.00K | 0.00 | 10.00K | 0.00 |
| Interest Expense | 98.00K | 476.00K | 816.00K | 775.00K | 338.00K | 319.00K | 152.00K | 0.00 | 0.00 | 845.10K | 931.00K | 694.07K |
| Depreciation & Amortization | 576.00K | 3.19M | 255.00K | 1.58M | 2.06M | 388.00K | 241.00K | 143.00K | 66.00K | 86.44K | 219.00K | 212.03K |
| EBITDA | -43.67M | -54.96M | -49.60M | -27.17M | -41.51M | -35.33M | -14.19M | -31.90M | -22.90M | -14.10M | -15.05M | -8.67M |
| EBITDA Ratio | -74.18% | -182.80% | -211.59% | -291.07% | -2,385.86% | -5,011.49% | -819.82% | -1,081.42% | -4,654.07% | 0.00% | 0.00% | 0.00% |
| Operating Income | -44.25M | -58.15M | -49.86M | -28.75M | -43.57M | -37.83M | -14.97M | -31.90M | -22.90M | -14.49M | -15.28M | -9.03M |
| Operating Income Ratio | -75.16% | -193.41% | -212.68% | -307.97% | -2,504.25% | -5,365.96% | -865.05% | -1,081.42% | -4,654.07% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 12.17M | 2.72M | -561.00K | 803.00K | 1.72M | 977.00K | 6.99M | 439.00K | 80.00K | -548.76K | -921.00K | -543.14K |
| Income Before Tax | -32.08M | -55.43M | -50.42M | -27.95M | -41.85M | -36.85M | -7.98M | -31.46M | -22.82M | -15.04M | -16.20M | -9.57M |
| Income Before Tax Ratio | -54.49% | -184.38% | -215.07% | -299.37% | -2,405.29% | -5,227.38% | -461.18% | -1,066.54% | -4,637.80% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 103.00K | 2.33M | -87.00K | -6.00K | 682.00K | -366.00K | -200.00K | -143.00K | -66.00K | 1.14M | 941.00K | 845.01K |
| Net Income | -32.18M | -57.76M | -50.33M | -27.94M | -42.53M | -36.49M | -7.78M | -31.46M | -22.82M | -15.04M | -16.20M | -9.57M |
| Net Income Ratio | -54.66% | -192.13% | -214.70% | -299.30% | -2,444.48% | -5,175.46% | -449.62% | -1,066.54% | -4,637.80% | 0.00% | 0.00% | 0.00% |
| EPS | -0.64 | -1.73 | -1.98 | -1.34 | -2.32 | -2.63 | -1.20 | -8.12 | -9.74 | -6.59 | -7.10 | -4.20 |
| EPS Diluted | -0.64 | -1.73 | -1.98 | -1.34 | -2.32 | -2.63 | -1.20 | -8.12 | -9.74 | -6.59 | -7.10 | -4.20 |
| Weighted Avg Shares Out | 50.00M | 33.44M | 25.48M | 20.83M | 18.36M | 13.85M | 6.48M | 3.87M | 2.34M | 2.28M | 2.28M | 2.28M |
| Weighted Avg Shares Out (Dil) | 50.00M | 33.44M | 25.48M | 20.83M | 18.36M | 13.85M | 6.48M | 3.87M | 2.34M | 2.28M | 2.28M | 2.28M |
Alpine Immune Sciences Announces Participation in the Bank of America Securities Healthcare Conference
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that the Company will participate in the 2023 Bank of America Securities Healthcare Conference. Date: Tuesday,...
Alpine Immune: Rebuilding Itself From Scratch, But Long Way To Go Before Proof
Last year, ALPN ditched its lead program after a second patient death in a CD28 molecule, a previously notorious pathway. ALPN has started all over again, with backing from a few big pharma.
Alpine Immune Sciences, Inc. (ALPN) Q4 2022 Earnings Call Transcript
Alpine Immune Sciences, Inc. (NASDAQ:ALPN ) Q4 2022 Earnings Conference Call March 23, 2023 4:30 PM ET Company Participants Temre Johnson - SD, IR Mitchell Gold - Executive Chairman, CEO Stanford Peng - President, Head of R&D Paul Rickey -...
Alpine Immune Sciences, Inc. (ALPN) Reports Q4 Loss, Lags Revenue Estimates
Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of -51.85% and 73.36%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Alpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today provided a corporate update and reported financial results for the fourth quarter ended December 31, 2022. “With...
Alpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today provided a corporate update and reported financial results for the fourth quarter ended December 31, 2022.
Alpine Immune Sciences to Present Povetacicept (ALPN-303) Phase 1 (RUBY-1) Study Data and Clinical Pharmacokinetic & Pharmacodynamic Modeling at Upcoming Scientific Conferences
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, will present posters at the American Society for Clinical Pharmacology & Therapeutics (ASCPT) Annual Meeting and at the...
Alpine Immune Sciences to Present Povetacicept (ALPN-303) Phase 1 (RUBY-1) Study Data and Clinical Pharmacokinetic & Pharmacodynamic Modeling at Upcoming Scientific Conferences
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, will present posters at the American Society for Clinical Pharmacology & Therapeutics (ASCPT) Annual Meeting and at the...
Alpine Immune Sciences to Present Povetacicept (ALPN-303) Phase 1 (RUBY-1) Study Data at the 2023 American Academy of Dermatology Annual Meeting
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, will present an ePoster with an oral presentation at the American Academy of Dermatology (AAD) Annual Meeting, highlighting...
Alpine Immune Sciences to Present Povetacicept (ALPN-303) Phase 1 (RUBY-1) Study Data at the 2023 American Academy of Dermatology Annual Meeting
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc.
Source: https://incomestatements.info
Category: Stock Reports